ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

potassium L-ascorbate

Its studies are led by Samsung Bioepis.

Furthest: phase 1, since Mar 26, 20261 company-led study, 1 open or runningNext primary completion: Jul 2030 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Samsung Bioepis11 open or runningphase 1since Mar 26, 2026Mar 26, 2026Jul 2030phase 1 · NCT07524348

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 26, 2026First study: phase 1 study in Advanced Solid TumorsFirst studyNCT07524348 · 149 planned · United States, Australia, South Korea and more

Ahead

  1. Jul 2030Primary completion: phase 1 study in Advanced Solid TumorsNCT07524348

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07524348Advanced Solid Tumors · United States, Australia, South Korea and more1RecruitingJul 2030149

How it is read

Names in the registry

  • “E303”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.